Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tak-715. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 20/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 1/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tak-715 SCHEMBL29435089 | 1.00 | MAPK14 (1.00) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| Tak-715 SCHEMBL29350215 | 1.00 | MAPK14 (1.00) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5201834 | 0.94 | MAPK14 (0.89) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL4257752 | 0.93 | MAPK14 (1.00) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5205012 | 0.92 | MAPK14 (0.85) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL31080012 | 0.91 | MAPK14 (0.90) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5200465 | 0.91 | MAPK14 (0.83) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5203222 | 0.91 | MAPK14 (0.83) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL4259120 | 0.91 | MAPK14 (0.90) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL5201247 | 0.90 | MAPK14 (0.82) | MAPK14IKBKBMAPK13PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-12065671-B2 | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-20 | — | — | US | claimed |
| EP-4345160-A2 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-03 | — | — | EP | claimed |
| CN-114807035-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2024-02-02 | — | — | CN | claimed |
| EP-3347456-B1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | US HEALTH (US) | 2023-12-27 | — | — | EP | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-20230151336-A1 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-18 | — | — | US | claimed |
| CN-114807035-A | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2022-07-29 | — | — | CN | claimed |
| CN-108473962-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2022-04-26 | — | — | CN | claimed |
| WO-2021216846-A9 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-16 | — | — | WO | claimed |
| US-7276527-B2 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-02 | — | — | US | claimed |
| EP-1180518-B1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-01-17 | — | — | EP | claimed |
| US-7101899-B1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | claimed |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | OHKAWA SHIGENORI | 2006-06-22 | — | — | US | claimed |
| WO-2006006691-A2 | SOLID DISPERSION OF A P38 MAP KINASE INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | WO | claimed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | claimed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | claimed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | claimed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | claimed |
| EP-1180518-A1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885IKBKB 119/4885MAPK13 72/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885IKBKB 132/4885MAPK13 23/4885 |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | ADORA3, MAPK4, MAPK3 | MAPK14 47/4885IKBKB 289/4885MAPK13 13/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | MAPK14 29/4885IKBKB 25/4885MAPK13 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.